Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Malignant bowel obstruction

Palliative and end-of-life care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Obstruction with perforation or ischaemia

Continuous severe pain, peritonism, fever, shock, rising lactate, free air or sudden clinical collapse suggests strangulation, ischaemia, perforation or sepsis.

Action: Use ABCDE care, stop oral and enteral intake, obtain intravenous access and urgent surgical review within the treatment ceiling. Give broad-spectrum antimicrobial and resuscitation treatment under the acute protocol when appropriate, provide non-oral analgesia and antiemetic and do not give prokinetic, stimulant laxative or rectal intervention.

Synopsis

Diagnose mechanical obstruction and its complications, assess whether surgery, stent or venting can achieve meaningful benefit, and provide coordinated non-oral analgesic, antiemetic, antisecretory, corticosteroid, hydration and mouth care when medical management is chosen.

  • Suspect malignant obstruction with colic or continuous pain, distension, nausea, vomiting, reduced flatus or stool and known intra-abdominal or pelvic cancer.
  • First-line safety assessment looks for peritonitis, ischaemia, perforation, strangulated hernia, aspiration, sepsis, severe dehydration and renal injury.
  • Contrast CT abdomen and pelvis is the gold-standard investigation for site, completeness, number of levels, complications, tumour burden and interventional planning.
  • Early multidisciplinary review separates a potentially correctable single-level obstruction from multifocal carcinomatosis or functional failure unlikely to benefit from surgery.
  • Surgery or stent is favoured when anatomy is correctable, performance and prognosis allow recovery, symptom benefit is meaningful and the patient accepts burden.
  • Nasogastric decompression provides short-term relief from large-volume vomiting; a venting gastrostomy can support longer symptom control when intervention will not restore transit.
  • In complete obstruction avoid metoclopramide, stimulant or bulk laxative and use non-prokinetic antiemetic, opioid, antisecretory medicine and a short corticosteroid trial.
  • In partial obstruction without colic, a cautious metoclopramide trial may improve transit, but stop immediately if colic or vomiting worsens.
  • The gold-standard plan names the branch, rescue and pump medicines, decompression, intake and hydration approach, review window and triggers for changing goal.

Key red flags

Peritonism, shock, fever, rapidly worsening continuous pain or lactate rise requires urgent surgery and sepsis assessment.

Faeculent vomiting, aspiration, severe dehydration or altered consciousness threatens airway, kidney function and medicine absorption.

Complete mechanical obstruction with colic is a contraindication to metoclopramide and stimulant or bulk laxatives.

A tense closed-loop obstruction, volvulus or incarcerated hernia can progress rapidly despite modest early imaging or examination findings.

Neutropenia, recent surgery, radiotherapy or immunotherapy broadens the differential to enterocolitis, leak, stricture and inflammatory toxicity.

Persistent high nasogastric output, oliguria, potassium disturbance or rising creatinine requires active fluid, electrolyte and renal medicine review.

Octreotide can cause glucose disturbance, bradycardia and biliary effects, while antimuscarinics can worsen retention, dry mouth and delirium.

Complicated obstruction

Peritonism, shock, fever, continuous escalating pain or lactate rise suggests ischaemia, perforation or sepsis.

Investigation priorities

01
First-line abdominal and hernia examinationFirst stepFirst line

Assess stability, hydration, distension, focal or colicky pain, peritonism, masses, scars, hernias, bowel sounds and rectal loading.

Management branches

Emergency assessmentExclude strangulation, perforation and sepsis

Obstruction symptoms accompany continuous severe pain, peritonism, instability, fever or rapid deterioration.

  1. Use ABCDE care, stop oral and enteral intake, obtain access and blood tests and call urgent surgical and acute oncology teams within the treatment ceiling.
  2. Arrange immediate CT or operative decision, give protocol antimicrobial and resuscitation care when indicated and provide non-oral analgesia and antiemetic.
  3. Avoid prokinetic, stimulant, bulk and rectal treatment and document the patient's capacity, intervention wishes and reassessment point.

Key medicines

Octreotide for obstructive secretionStart 300 micrograms over 24 hours by continuous subcutaneous infusion in many palliative protocols, titrating commonly within 300 to 600 micrograms daily according to output and specialist advice.Monitor glucose, pulse, abdominal pain and injection site; gallbladder effects and interactions occur, and hepatic impairment may prolong exposure.
Hyoscine butylbromide for colic and secretionGive 20 mg subcutaneously as needed and use 60 to 120 mg over 24 hours by continuous infusion when repeated benefit and local compatibility guidance support it.Dry mouth, urinary retention, tachycardia, glaucoma and anticholinergic burden require review; do not combine blindly with other antisecretory agents.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • Scottish palliative bowel obstruction guidelineAssessment, prokinetic contraindications, antisecretory treatment and subcutaneous doses.
  • NICE NG151 colorectal cancerStenting, surgery and management of obstructing colorectal cancer.
  • NICE NG142 end of life service deliveryMultidisciplinary coordination, patient goals and timely access to specialist palliative care.
  • NICE CG32 nutrition supportEnteral and parenteral nutrition indications, consent, monitoring and refeeding safety.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom